CD274 and head and neck squamous cell carcinoma: Since the initial approval, the PD-L1 IHC 22C3 pharmDx assay approval has been extended to patients with gastroesophageal and gastroesophageal junction cancer, cervical cancer, UC, HNSCC, and TNBC.